Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | EDNRA | P25101 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levosemotiadil SCHEMBL678293 | 1.00 | CYP3A4 (0.68) | CYP3A4EDNRACACNA1SDRD2DRD3 | |
| Semotiadil SCHEMBL29396077 | 1.00 | CYP3A4 (0.68) | CYP3A4EDNRACACNA1SDRD2DRD3 | |
| Semotiadil SCHEMBL678676 | 1.00 | CYP3A4 (0.68) | CYP3A4EDNRACACNA1SDRD2DRD3 | |
| SCHEMBL7376974 | 0.98 | CYP3A4 (0.65) | CYP3A4EDNRACACNA1SDRD2DRD3 | |
| SCHEMBL10676730 | 0.98 | CYP3A4 (0.65) | CYP3A4EDNRACACNA1SDRD2DRD3 | |
| Oxalic Acid SCHEMBL9748438 | 0.96 | CYP3A4 (0.66) | CYP3A4EDNRADRD2DRD3MAPK1 | |
| Semotiadil SCHEMBL7382921 | 0.94 | CYP3A4 (0.64) | CYP3A4EDNRADRD2DRD3MEN1 | |
| Levosemotiadil SCHEMBL30873510 | 0.94 | CYP3A4 (0.64) | CYP3A4EDNRADRD2DRD3MEN1 | |
| Semotiadil SCHEMBL7299290 | 0.94 | CYP3A4 (0.64) | CYP3A4EDNRADRD2DRD3MEN1 | |
| Semotiadil SCHEMBL7299286 | 0.94 | CYP3A4 (0.64) | CYP3A4EDNRADRD2DRD3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2333 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299348-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. | 2024-09-12 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| WO-2022150461-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-9982042-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20170166632-A1 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent | ONCOMED PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | claimed |
| EP-2480224-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | ACRAF (IT) | 2017-05-24 | — | — | EP | claimed |
| US-9511139-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| EP-3072526-A1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | Oncomed Pharmaceuticals, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| US-6281208-B1 | E.G., 3,4-DIHYDRO-2-(5-METHOXY-2-(3-(N-METHYL-N-(2-((3,4-METHYLENEDI OXY) PHENOXY)ETHYL)AMINO)PROPOXY)PHENYL)-4-METHYL-3-OXO-2H-1,4-BENZ | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-08-28 | — | — | US | claimed |
| EP-0492164-B1 | Therapeutic agent for glaucoma containing 2-phenyl-3-oxo-2H-1,4-benzothiazine derivatives | SANTEN PHARMACEUTICAL CO LTD (JP) | 1996-02-07 | — | — | EP | claimed |
| EP-0639986-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0492164-A1 | Therapeutic agent for glaucoma containing 2-phenyl-3-oxo-2H-1,4-benzothiazine derivatives | SANTEN PHARMACEUTICAL CO., LTD (JP) | 1992-07-01 | — | — | EP | claimed |